iMDx raises $26 million in registered direct offering

Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) announced it entered into agreements with institutional investors for a registered direct offering of 4,525,976 shares of common stock at $5.75 per share. The offering is expected to close on February 12, 2026.

The company will receive approximately $26.0 million in gross proceeds before deducting placement agent fees and other expenses. Lake Street Capital Markets serves as the sole placement agent for the offering.

Bio-Rad Laboratories, a significant shareholder of iMDx, participated in the offering on the same terms as other investors.

The company stated it intends to use net proceeds for general corporate purposes, including research and development in the transplantation category. Specifically, iMDx plans to expand its GraftAssure product offering beyond kidney transplant rejection testing into other organs, with immediate focus on heart transplant rejection testing.

The securities are being offered through a shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission on August 1, 2024, and declared effective on August 7, 2024.

Insight Molecular Diagnostics describes itself as a diagnostics technology company focused on molecular diagnostic testing to improve patient outcomes.

You May Also Be Interested In

• DEFSEC Technologies (DFSC) files for 4.05M share offering by selling stockholders
• 17EdTech approves $10 million share repurchase program
• Eledon files IND for islet cell trial, eyes Phase 3 kidney study